# Philippe Boucheron

> Philippe Boucheron is a private equity investor at Bpifrance backing Medical and Health Care. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Bpifrance](https://shizune.co/investors/profile/bpifrance)
- Location: Paris, France
- Total investments: 7
- Last investment: Sep 2024
- Lead investor: 29%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/philippe-boucheron-3101582/

Philippe Boucheron is a private equity investor at Bpifrance in Paris focused on Medical and Health Care. Mr. Boucheron is Investment Director at Bioam, a biotechnology investment fund. From 1993 to 1996, Mr. Boucheron worked at BioCapital LP, one of Canada’s largest venture capital funds focusing on biotech. From 1997 to 2000, he directed the mid-caps equity research team at the Paris office of ING Barings Ferri, where he spent a significantamount of his time following French and European BioTech companies. Mr. Boucheron holds a degree in Biochemical Engineering and Microbial Genetics from the Institut National des Sciences Appliqués in Toulouse He also has an MSc in Biochemical Engineering from the Ecole Polytechique of Montreal and a MBA from INSEAD.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 29% |
| Health Care | 2 | 29% |
| Therapeutics | 2 | 29% |
| Biotechnology | 2 | 29% |
| Genetics | 1 | 14% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Private Equity | 2 | 29% |
| Series A | 1 | 14% |
| Series B | 1 | 14% |
| Funding Round | 1 | 14% |
| Post-IPO Equity | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| HEPTA Medical | HEPTA Medical develops a sensor, embedded into a bronchoscopic or percutaneous ablation catheter, which provides temperature-based feedback. This enables real-time dosing to precisely target and ablates pulmonary nodules, the precursor of lung cancer, without the need for surgery or radiation. | $6.3M | Series A | Sep 04, 2024 |  |
| Advicenne | Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Parisand Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France. | $17.6M |  | Mar 20, 2017 |  |
| Advicenne Pharma SA | Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from rare renal diseases. | $17.6M | Private Equity | Mar 20, 2017 |  |
| Advicenne | Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Parisand Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France. | $18.2M | Private Equity | Mar 20, 2017 |  |
| Advicenne | Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Parisand Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France. | $18.2M | Private Equity | Mar 20, 2017 |  |
| IntegraGen | IntegraGen is a French biotech company based on the Genopole life science park in Evry, near Paris. It leverages its unique intellectual property, research expertise and privileged access to sample libraries to develop molecular markers for central nervous system and metabolic diseases. IntegraGen notably uses its proprietary technology platformsto provide genomics services to the pharmaceutical industry, biotech firms and other research providers. | $8.8M | Series B | Nov 17, 2005 |  |
| Advicenne | Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Parisand Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France. | $3M | Post-IPO Equity |  |  |

7 of 7 investments shown.

## Co-investors
- [IXO Private Equity](https://shizune.co/investors/profile/ixo-private-equity) — VC Fund, 4 deals together
- [Cemag Invest](https://shizune.co/investors/profile/cemag-invest) — VC Fund, 3 deals together
- [InnoBio](https://shizune.co/investors/profile/innobio) — VC Fund, 3 deals together
- [IRDI](https://shizune.co/investors/profile/irdi-midi-pyrenees) — VC Fund, 3 deals together
- [IRDI SORIDEC Gestion](https://shizune.co/investors/profile/irdi-soridec-gestion) — VC Fund, 3 deals together
- [MI Care](https://shizune.co/investors/profile/mi-care) — VC Fund, 3 deals together

## About Bpifrance

VC Fund · Maisons-alfort, France

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.

5 contacts available at Bpifrance.

| Name | Title | Profile |
| --- | --- | --- |
| Adrien Neel | Investment Director | https://shizune.co/investors/profile/adrien-neel |
| Cédric Clement | Senior Investment Director \| Bpifrance Deeptech Venture | https://shizune.co/investors/profile/c%C3%A9dric-clement |
| Charlotte Corbaz | Investment Drector - Large Venture | https://shizune.co/investors/profile/charlotte-corbaz |
| Clarisse Blandin | Investment director | https://shizune.co/investors/profile/clarisse-blandin-2 |
| Laure Michel | Investment Director | https://shizune.co/investors/profile/laure-michel |

## Similar investors

### Similar stage
- [Foresight Group](https://shizune.co/investors/profile/foresight-group) — VC Fund
- [YFM Equity Partners](https://shizune.co/investors/profile/yfm-equity-partners) — VC Fund
- [Fondaction](https://shizune.co/investors/profile/fondaction) — VC Fund

## FAQ

### What does Philippe Boucheron invest in?

Philippe Boucheron invests primarily in Medical, Health Care and Therapeutics startups, most often at Private Equity and Series A stage. Most of the 7 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Philippe Boucheron last invest?

The most recent investment recorded for Philippe Boucheron closed in Sep 2024. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co